Meristem Therapeutics

France's Meristem Therapeutics, spun out of seed producer Groupe Limagrain, is using transgenic plants to produce commercial quantities of purified protein-based pharmaceuticals. It hopes that the success of its phase II product, lipase, will help convince an as-yet skeptical pharmaceutical industry of the value--both in terms of safety, cost and efficiency--of plant-derived therapeutics.

In 1992, Groupe Limagrain, the world's fourth-largest seed producer, initiated a program to produce recombinant therapeutic proteins from plants. Three years later, Molecular Pharming, as the project was called, produced its first harvest, with the successful expression of human hemoglobin in transgenic tobacco plants. By 1998, the project had progressed far enough for Limagrain (which wanted to focus on its seed producing activities) to spin it off as a fully owned subsidiary, Meristem Therapeutics. The following year, Limagrain freed up Meristem to raise €18.3 million ($16.2 million) in first round funding as an independent biotech.

Transgenic plants are increasingly being used as vehicles to produce recombinant protein-based pharmaceuticals, addressing the growing problem of limited production...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Business

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JXR And Alexion Build Upon Existing Gene Therapy Alliances

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.